SP-0642: OLIGOCARE, the EORTC ESTRO initiative for oligometastasis: a pragmatic platform

Ost, P.

doi:10.1016/s0167-8140(18)30952-6

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in the absence of prospective randomised trials, the panel believed that a large national registry is needed to prospectively collect data of patients treated for OMPC. Prospective initiatives, such as the registry trial Oligo-Care initiated by EORTC-ESTRO, will evaluate changing patterns of care of oligometastatic disease [32].…”

Section: Treatmentmentioning

confidence: 99%

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Aluwini¹,

Mehra

Lolkema

et al. 2020

European Urology Oncology

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Aluwini¹,

Mehra

Lolkema

et al. 2020

European Urology Oncology

View full text Add to dashboard Cite

“…After the results of the trial, there is now increasing consideration for the use of ablative RT in patients with oligometastatic disease, with a focus on defining oligometastatic disease and clinical criteria for which ablative RT should be applied. The European Society for Radiotherapy and Oncology and European Organization for Research and Treatment of Cancer recently published a consensus recommendation on the characterization and classification of oligometastatic disease, 22 with the ongoing prospective OligoCare registry trial aiming to evaluate the proposed classification and nomenclature 23 . Of even greater importance is identifying patient and disease characteristics predictive of the survival benefit of radical local therapy for metastatic lesions.…”

Section: Discussionmentioning

confidence: 99%

“…The European Society for Radiotherapy and Oncology and European Organization for Research and Treatment of Cancer recently published a consensus recommendation on the characterization and classification of oligometastatic disease, 22 with the ongoing prospective OligoCare registry trial aiming to evaluate the proposed classification and nomenclature. 23 Of even greater importance is identifying patient and disease characteristics predictive of the survival benefit of radical local therapy for metastatic lesions. Prognostic factors such as primary tumor site/histology, timing of metastases, location of metastasis, number and type of organs involved, disease response to CTX, mutation profile, status of the primary tumor, and technical feasibility of treating the lesions may need to be considered in the decision-making for radical local therapy.…”

Section: Discussionmentioning

confidence: 99%

Liver Metastasis–Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients

Lee¹,

Kim

Oladeru

et al. 2021

Pancreas

View full text Add to dashboard Cite

Objectives: We evaluated the outcomes of metastatic pancreatic cancer (MPC) patients who underwent liver metastases (LMs)-directed ablative radiotherapy (RT) and sought to characterize patients with more favorable prognosis.Methods: A retrospective analysis of 76 MPC patients who underwent ablative RT (median dose, 50 Gy) to LM at 3 academic centers between 2008 and 2018 was performed. Endpoints were local control (LC), progression-free survival, and overall survival (OS) since RT.Results: Median follow-up was 10.9 months. Liver metastases were metachronous in 68%. Before RT, LM was responsive/stable on chemotherapy (CTX) in 36% whereas progressive in 43%. Median carbohydrate antigen 19-9 (CA 19-9) at RT was 334 U/mL. After RT, 32% had ≥6 months of CTX break. Twelve-month outcomes were: LC, 66%; progression-free survival, 7%; and OS, 38%. On multivariable analysis, Eastern Cooperative Oncology Group 2-3 (hazard ratio [HR], 13.49; P < 0.01), progressive LM on CTX (HR, 3.26; P < 0.01), and higher CA 19-9 (log 10 scale; HR, 1.39; P < 0.01) at RT predicted worse OS. Conclusions:Ablative RT to LM in setting of MPC may offer LC of systemic disease and thus quality time off CTX. Selected patients with good performance status, stable/responsive LM on CTX, and lower CA 19-9 have more favorable prognosis.

show abstract

“…Several trials are currently further exploring the role of SABR as MDT in OMD, such as SABR-COMET-3, SABR-COMET-10, and the OligoCare and OligoRare registry projects. [25][26][27] This trial has several limitations. First, the design was not randomized.…”

Section: Discussionmentioning

confidence: 99%

Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial

Mercier

Claessens

Buys

et al. 2021

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Increasing evidence suggests that patients with a limited number of metastases benefit from SABR to all lesions. However, the optimal dose and fractionation remain unknown. This is particularly true for bone and lymph node metastases. Therefore, a prospective, single-center, dose-escalation trial was initiated. Methods: Dose-Escalation trial of STereotactic ablative body RadiOtherapY for non-spine bone and lymph node metastases (DESTROY) was an open-label phase 1 trial evaluating SABR to nonspine bone and lymph node lesions in patients with up to 3 metastases. Patients with European Cooperative Oncology Group performance status 1, an estimated life expectancy of at least 6 months, and histologically confirmed nonhematological malignancy were eligible. Three SABR fractionation regimens, ie, 5 fractions of 7.0 Gy versus 3 fractions of 10.0 Gy versus a single fraction of 20.0 Gy, were applied in 3 consecutive patient cohorts. The rate of !grade 3 toxicity, scored according to the Common Toxicity Criteria for Adverse Events v. 4.03, up to 6 months after SABR, was the primary endpoint. The trial was registered on clinicaltrials.gov (NCT03486431). Results: Between July 2017 and December 2018, 90 patients were enrolled. In total 101 metastases were treated. No !grade 3 toxicity was observed in any of the enrolled patients (95% CI 0.0%-12.3% for the first cohort with 28 analyzable patients; 95% CI 0.0%-11.6% for the second and third cohort with 30 analyzable patients each). Treatment-related grade 2 toxicities occurred in 4 out of 30 versus 2 out of 30 versus 2 out of 30 patients for the 5, 3 and 1 fraction schedule, respectively. Actuarial local control rate at 12 months was 94.5%. Conclusion: All 3 treatment schedules were feasible and effective with remarkably low toxicity rates and high local control rates. From a patient and resource point of view, the single-fraction schedule is undoubtedly most convenient.

show abstract

SP-0642: OLIGOCARE, the EORTC ESTRO initiative for oligometastasis: a pragmatic platform

Cited by 4 publications

References 0 publications

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Liver Metastasis–Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients

Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial

Contact Info

Product

Resources

About